Addex Therapeutics Ltd (ADXN) - Forward P/S Multiple
Swiss biotech Addex Therapeutics (ADXN) is protected by the humanitarian status of medicine, which eliminates political risks. Strict climate control during drug delivery ensures test safety, although it increases logistics costs. Revenues are based on the commercialization of neurotherapy for the treatment of Parkinson's disease. The forward price-to-sales ratio on this chart shows that the metric value is 56.40.
Financial and market metric breakdowns for Addex (ADXN)
- current price and projected stock value:
- market capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
- business earnings and investment ratios data:
ADXN - Net Financial Result|Projected Future Earnings Addex Therapeutics|ADXN - Price to Earnings Ratio|Future Price to Earnings Addex Therapeutics, Ltd.|ADXN - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Addex|ADXN - Operating profit EBITDA|Net earnings per share (EPS TTM) Addex Therapeutics|ADXN - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months addextherapeutics.com|ADXN - Earnings per share growth this year|Net earnings per share growth forecast for next year Addex Therapeutics
- company sales and revenue statistics:
Initial company analysis:Addex Therapeutics Ltd (ADXN)
Holding unique CNS patents and maintaining barriers to entry for new players through extensive R&D, Addex Therapeutics (ADXN) operates under strict FDA oversight. The forward P/S multiple compares the company's current valuation with projected revenue to determine the premium paid for expected success. By analyzing this forward P/S multiple, an investor assesses whether market expectations regarding the business acquisition value are justified.
Competitors of Addex Therapeutics
Forward P/S Multiple BIIB (Biogen)|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|Market Cap to Future Revenue Ratio Axsome Corp|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|xenon-pharma.com - Forward Price to Sales|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Supernus Pharmaceuticals, Inc.|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI: Future Price to Revenue|Forward P/S Multiple HRMY (Harmony Biosciences)|biohavenpharma.com (BHVN) - Market Cap to Future Revenue Ratio|AMLX: Forward Price-to-Revenue Multiple|TRVI - Forward P/S Multiple|PRAX (Praxis Medicines) - Forward Price-to-Revenue Multiple|AVXL: Price to Expected Revenue Ratio|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Prothena Corporation (PRTA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALEC|Forward Price-to-Revenue Multiple Annexon Biosciences ANNX|Price-to-Projected Revenue Ratio Omeros OMER|Market Cap to Expected Sales Ratio Neurogene Therapeutics (NGNE)|AC Immune - Forward P/S Multiple|VYGR - Forward P/S Multiple|NMRA: Forward P/S Multiple|Market Cap to Projected Revenue SCLX|Forward Price-to-Revenue Multiple TVGN|Market Cap to Projected Revenue ACOG (Alpha Cognition Corp)|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|inhibikase.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|acumenpharm.com (ABOS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|PEPG - Market Cap to Future Revenue Ratio|Forward P/S Multiple JUNS (Jupiter Neurosciences Inc)|Forward P/S Multiple relmada.com RLMD|Annovis Bio - Forward P/S Multiple|GRCE (Grace Therapeutics, Inc.) - Market Cap to Projected Revenue|AIFF: Forward P/S Multiple|Market Cap to Projected Revenue KLTO|NRSN (NeuroSense Therapeutics Ltd) - Forward P/S Multiple|Market Cap to Future Revenue Ratio revivapharma.com RVPH|Forward Price-to-Revenue Multiple MTVA (MetaVia Inc)|NeurAxis Inc. - Market Cap to Projected Revenue|Helius Medical Technologies - Forward Price-to-Revenue Multiple|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|minervaneurosciences.com - Price to Expected Revenue Ratio|ATHA: Forward P/S Multiple|Alzamend Neuro - Forward Price to Sales|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Protagenic PTIX|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Forward Price to Sales|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Forward P/S Multiple Brainstorm Cell Therapeutics Inc. BCLI|CARA - Price-to-Projected Revenue Ratio|Future Price to Revenue CHRO|ELYM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Forward Price-to-Revenue Multiple LBPH|Forward P/S Multiple Marinus Pharmaceuticals Inc|Forward Price-to-Revenue Multiple NKGN (NKGen)|Price to Expected Revenue Ratio NRBO|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Market Cap to Expected Sales Ratio synaptogen.com (SNPX)|Trevena - Forward P/S Multiple|Vigil Neuroscience (VIGL) - Forward Price-to-Revenue Multiple|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|CERE - Market Cap to Expected Sales Ratio
